A systemic review and metanalysis on five clinical phase 1/2 trials exploring the efficacy of anti-SHH agents vismodegib and sonidegib showed that the pooled objective response rate (ORR) of SHH-inhibitors was 37% in SHH-driven medulloblastomas. The gene discussed is SHH; the disease is medulloblastoma.